Impact of Liraglutide 3.0 on Body Fat Distribution

NCT03038620 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

235

Enrollment

OTHER

Sponsor class

Conditions

Obesity, Visceral
Cardiovascular Diseases
Fat Disorder

Interventions

DRUG: Liraglutide
DRUG: Placebo

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]